AC Immune S.A.
ACIU
NASDAQ·Healthcare·Biotechnology·Mkt cap $291.1M
$2.86
▼ -2.39%
P/E
-5.20
Mkt Cap
$291.1M
52-Wk Range
$2.10–$4.00
52-Week Range
$2.10 - $4.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 30.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Mild headwinds expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+27.1% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ACIU right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 5, 2026
Reported EPS of $0.03 vs -$0.10 consensus (+128.7% surprise). Revenue of $9.8M vs $9.6M expected (+2.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+128.7%
Revenue trend · last 8Q
—
—
—
+90%
-96%
-70%
+12%
+1030%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$32.6M
$1.5M
$1.3M
$1.7M
$1.2M
$432.2K
$1.4M
$18.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
12.4%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 1, 2026
vs Industry
How ACIU stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.